Composition capable of rapidly removing dark circles and resisting aging for long time and application of composition

Abstract

The invention discloses a long-acting anti-aging composition capable of quickly removing dark circles and application of the composition. The composition is prepared from the following components: beta-nicotinamide mononucleotide, glutathione, acetyl hexapeptide-8, acetyl tetrapeptide-5, snake venom-like peptide, arginine / lysine polypeptide, tocopheryl acetate and ergothioneine. According to the present invention, multiple functions are adopted, such that the effects of dark circle removing, repair, elasticity recovery, aging resistance and the like are provided so as to block the generation of dark circle, and the normal function of skin is ensured. The composition disclosed by the invention has the effect of quickly removing dark circles, and when the eye cream contains the composition, the eye cream can effectively remove the dark circles and has an obvious and quick effect within 15 minutes; after being used for a long time, the eye mask can remove dark circles and play a good control role.

Description

Technical Field

[0001] The present application relates to the technical field of cosmetics, and in particular to a composition for rapidly removing dark circles and providing long-term anti-aging effects and its application. Background Art

[0002] The formation of dark circles is affected by various factors. Staying up late for a long time, irregular work and rest, and lack of sleep can cause the blood flow in the eye skin blood vessels to be too slow, resulting in stagnation, insufficient tissue oxygen supply, and excessive accumulation of metabolic waste in the blood vessels, causing eye pigmentation. As melanin continues to accumulate, dark circles appear on the eye skin. Moreover, with age, the epidermal tissue of the eye skin becomes dry and thinner, collagen and elastin are gradually lost, and the metabolism of the eyes is slow, which forms eye wrinkles, dark circles and eye bags. There are two types of dark circles. One is cyan dark circles, which is caused by the retention of venous blood in the microvessels and the slow metabolism of metabolic waste in the veins; the other is brown dark circles, which are mainly caused by eye pigmentation due to incomplete melanin production and metabolism.

[0003] In order to remove dark circles and delay the aging of the skin around the eyes, in addition to ensuring adequate sleep and developing good living habits and eye habits in daily life, a common method is to use eye cosmetics. There are many eye cosmetics on the market, but most of them have unclear effects or single effects. Some products can take effect quickly, but after using them for a period of time, they are prone to side effects or bring new problems such as fat particles, which increase the burden on the eyes. Therefore, there is a need for an eye cream product that can quickly remove dark circles and have long-lasting anti-aging effects. Summary of the invention

[0004] In order to solve the above problems, the present invention provides a composition for quickly removing dark circles and long-term anti-aging and its application. The composition prepared in the present invention is composed of β-nicotinamide mononucleotide, polypeptide complex a, polypeptide complex b, tocopherol acetate and ergothioneine, which can solve the root causes of dry eye skin, fine lines, sagging, eye bags and dark circles from the cellular level, and is applied to the development of eye care products, which has excellent moisturizing, lightening fine lines, firming, removing eye bags and dark circles. The effect, long-term use, can comprehensively improve skin function and make the skin younger.

[0005] To achieve the above objectives, the present invention provides a composition for rapidly removing dark circles and providing long-term anti-aging effects, comprising β-nicotinamide mononucleotide, polypeptide complex a, polypeptide complex b, tocopherol acetate and ergothioneine.

[0006] Optionally, the composition comprises, by weight, 0.1-2 parts of β-nicotinamide mononucleotide, 0.052-2.15 parts of polypeptide complex a, 0.002-0.2 parts of polypeptide complex b, 0.1-2 parts of tocopherol acetate, and 0.01-0.05 parts of ergothioneine.

[0007] Preferably, the composition comprises, by mass, 0.5-1.5 parts of β-nicotinamide mononucleotide, 0.11-1.04 parts of polypeptide complex a, 0.02-0.1 parts of polypeptide complex b, 0.5-1.5 parts of tocopherol acetate, and 0.02-0.04 parts of ergothioneine;

[0008] Preferably, the composition comprises, by mass, 1 part of β-nicotinamide mononucleotide, 0.52 parts of polypeptide complex a, 0.065 parts of polypeptide complex b, 1 part of tocopherol acetate, and 0.03 parts of ergothioneine.

[0009] Optionally, the polypeptide complex a comprises 0.05-2 parts of glutathione, 0.001-0.1 parts of acetyl hexapeptide-8, and 0.001-0.05 parts of acetyl tetrapeptide-5, and the polypeptide complex b comprises 0.001-0.1 parts of snake venom peptide and 0.001-0.1 parts of arginine / lysine polypeptide.

[0010] Preferably, the polypeptide complex a comprises 0.1-1 parts of glutathione, 0.005-0.02 parts of acetyl hexapeptide-8, and 0.005-0.02 parts of acetyl tetrapeptide-5, by weight; the polypeptide complex b comprises 0.01-0.05 parts of snake venom peptide and 0.01-0.05 parts of arginine / lysine polypeptide;

[0011] Preferably, the polypeptide complex a comprises 0.5 parts of glutathione, 0.01 parts of acetyl hexapeptide-8, and 0.01 parts of acetyl tetrapeptide-5; preferably, the polypeptide complex b comprises 0.025 parts of snake venom peptide and 0.04 parts of arginine / lysine polypeptide.

[0012] The present invention also provides a method for preparing a lotion for rapidly removing dark circles and providing long-lasting anti-aging effects, comprising the following steps:

[0013] S1. The oil composition, the thickener and the humectant are stirred and mixed to obtain phase A;

[0014] S2. stirring and mixing β-nicotinamide mononucleotide, ergothioneine, polypeptide complex a and water to obtain phase B;

[0015] S3. stirring and mixing tocopherol acetate, polypeptide complex b, and emulsifier to obtain phase C;

[0016] S4. Mix phases A, B and C to obtain an emulsion.

[0017] Optionally, in step S1, the oil composition is composed of at least one of polydimethylsiloxane, cyclopentasiloxane, polydimethylsiloxane cross-linked polymer, cyclopentasiloxane, and TEA dodecylbenzenesulfonate; the thickener is composed of at least one of acryloyldimethyltaurate / VP copolymer, carbomer, sodium acrylate / acryloyldimethyltaurate / isohexadecane / polysorbate-80; and the moisturizer is composed of at least one of hyaluronic acid and sodium hyaluronate.

[0018] Optionally, in step S3, the emulsifier is composed of at least one of glycerol, phenoxyethanol, and ethylhexylglycerin.

[0019] Optionally, in step S4, the pH of phases A, B and C is adjusted to 6.2, and the mixture is stirred and mixed in a water bath at 40° C. for 30 minutes to obtain an emulsion.

[0020] The present invention also provides the use of any of the above-mentioned compositions in cosmetics, health products, and medicines, wherein the use includes the composition being made into an emulsion, solution, paste, gel, or spray formulation.

[0021] The synergistic effect mechanism between the components in this application:

[0022] The β-nicotinamide mononucleotide used in this application can be converted into nicotinamide adenine dinucleotide (NAD + coenzyme), so supplementing β-nicotinamide mononucleotide can increase NAD in the body + Coenzyme content, restore mitochondrial energy, activate the body's energy metabolism, stimulate the metabolism and repair of various aging tissues, extend cell life, increase ATP production, and then improve the body's metabolic capacity, thereby delaying, improving, and preventing aging, or improving age-induced metabolic disorders and geriatric diseases.

[0023] The polypeptide complex a used in the present application includes glutathione, acetyl hexapeptide-8, and acetyl tetrapeptide-5, wherein glutathione is a tripeptide composed of glutamic acid, cysteine ​​and glycine, which can help maintain the normal function of the immune system and has antioxidant and integrated detoxification effects; acetyl hexapeptide-8 can instantly remove dynamic lines and tighten the skin: it imitates the N-terminus of SNAP-25 and competes with natural proteins for binding sites in the SNARE protein complex, making it impossible for neuronal vesicles to effectively release neurotransmitters, resulting in weakened muscle contraction, thereby effectively and quickly preventing the formation of dynamic lines, and effectively reorganizing collagen elasticity, increasing the activity of elastin, relaxing facial lines, and improving relaxation; acetyl tetrapeptide-5 has the effects of preventing fluid accumulation in eye bags, diluting dark circles, increasing vascular permeability, inhibiting angiotensin converting enzyme, inhibiting collagen glycosylation, increasing skin elasticity, and promoting skin smoothness.

[0024] The polypeptide complex b used in the present application includes snake venom peptides and arginine / lysine peptides, wherein the snake venom peptides (INCI name: dipeptide diaminobutyryl benzylamide diacetate) mainly act on the post-protrusion model and are reversible antagonists of muscle nicotinic acetylcholine receptors (nmAChR). They bind to the ε subunit of nmAChR to block the binding of acetylcholine to the receptor, ultimately leading to receptor closure. In the closed state, sodium ions cannot be taken in, depolarization cannot be achieved, nerve excitation transmission is blocked, and muscles relax, thereby smoothing wrinkles without affecting the expression of facial expressions; arginine / lysine peptides are biomimic conotoxin peptides, which provide very strong muscle relaxation after sorting and artificial synthesis, and provide rapid and immediate anti-wrinkle effects. Arginine / lysine peptides are highly folded peptides with strong penetration, high stability, and targeted relaxation effects on muscles.

[0025] The tocopherol acetate used in this application is a vitamin E derivative, which has the effect of preventing the oxidation of cell membranes and unsaturated fatty acids in cells during skin metabolism, thereby protecting the integrity of cell membranes and preventing aging. Topical products containing tocopherol acetate also have strong reducing properties, which can eliminate cell free radicals and reduce the damage of ultraviolet rays to the skin.

[0026] The ergothioneine (EGT) used in the present application is a rare natural chiral amino acid and an important natural active substance in the body. It plays a role in anti-oxidation, scavenging singlet oxygen, hydroxyl free radicals, hypochlorous acid and hydroperoxyl free radicals, detoxification, maintaining DNA biosynthesis, normal cell growth and cell immunity, preventing ultraviolet radiation damage, regulating redox reactions in cells, participating in intracellular energy regulation and cell physiological protection, and other functions.

[0027] The beneficial effects of the present invention are embodied in:

[0028] 1. The present invention rationally compounds β-nicotinamide mononucleotide, glutathione, acetyl hexapeptide-8, acetyl tetrapeptide-5, snake venom peptide, arginine / lysine polypeptide, tocopherol acetate and ergothioneine, and utilizes the synergistic effect of different "neuroinhibitors" of arginine / lysine polypeptide, acetyl hexapeptide-8 and snake venom peptide to relax the eye muscles for dynamic and static lines around the eyes, thereby reducing the formation of fine lines; acetyl tetrapeptide-5 is used to change the microcirculation of the eye area and the osmotic pressure of the liquid to reduce edema, thereby effectively eliminating edema, eye bags and dark circles; at the same time, glutathione, tocopherol acetate, ergothioneine and β-nicotinamide mononucleotide are used as a group of antioxidants to form a renewable antioxidant network system, which synergistically inhibits tyrosinase activity and scavenges free radicals, and better resists oxidation and glycation. Short-term use can quickly remove dark circles. Long-term use can reduce wrinkles, plump up and regenerate skin, from immediate to long-term, from the outside to the inside, to rejuvenate the skin and achieve long-lasting anti-aging effects.

[0029] 2. The present invention has a multi-pronged approach, which can repair, restore elasticity, and resist aging while removing dark circles, thereby preventing the formation of dark circles and ensuring the normal function of the skin. In addition, the composition of the present invention also has the effect of quickly removing dark circles. When the eye cream contains the composition, the eye cream can effectively remove dark circles, and the effect is obvious within 15 minutes, and the effect is rapid. Long-term use can remove dark circles and play a good control role.

[0030] 3. The raw materials provided by the present invention are environmentally friendly, healthy, non-toxic, non-addictive, and can be used for a long time. They can activate cells, promote collagen synthesis, scavenge free radicals, inhibit tyrosinase activity, etc., and have the effects of whitening, removing spots and reducing wrinkles on the skin, improving the skin condition in all directions, thereby achieving a long-term anti-aging effect. It can be used alone as an emulsion, solution, paste, gel or spray formulation or used in combination with other skin care products. DETAILED DESCRIPTION

[0031] In order to more clearly illustrate the overall concept of the present invention, a detailed description is given below by way of examples.

[0032] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways different from those described herein. Therefore, the protection scope of the present invention is not limited to the specific embodiments disclosed below.

[0033] Unless otherwise specified, the raw materials, reagents or devices used in the following examples can be obtained from conventional commercial channels or by existing known methods; unless otherwise specified, the methods used in the examples of the present invention are methods known to those skilled in the art. Among them, the arginine / lysine polypeptide used is L-arginine / L-lysine polypeptide with CAS number 31014-78-5, purchased from Shanghai Xiarui Pharmaceutical Technology Co., Ltd.

[0034] Hereinafter, the composition having the functions of quickly removing dark circles and long-term anti-aging, as well as the preparation method and application thereof of the present invention will be described in detail in combination with exemplary embodiments.

[0035] In order to better reflect the efficacy of the composition, the specific implementation methods of the present application are to prepare the composition into an emulsion form for experimental testing. However, in specific applications, it is not limited to an emulsion product form. For example, the composition in the present application can also be prepared into a solution, paste, gel or spray product form.

[0036] Example 1 Preparation of the composition

[0037] The preparation method of product 1# comprises the following steps:

[0038] 1. Stir and disperse 3g of polydimethylsiloxane, 3g of cyclopentasiloxane, 18g of polydimethylsiloxane crosspolymer (and) cyclopentasiloxane (and) TEA dodecylbenzenesulfonate, 0.1g of carbomer, 0.55g of acryloyldimethyl taurate / VP copolymer, 0.8g of sodium acrylate / acryloyldimethyl taurate / isohexadecane / polysorbate-80, and 1g of sodium hyaluronate to obtain phase A;

[0039] 2. Stir and disperse 1 g of β-nicotinamide mononucleotide, 0.5 g of glutathione, 0.01 g of acetyl hexapeptide-8, 0.01 g of acetyl tetrapeptide-5, 0.03 g of ergothioneine, and 66 g of water to obtain phase B;

[0040] 3. Stir and disperse 1 g of tocopherol acetate, 0.025 g of snake venom peptide, 0.04 g of arginine / lysine polypeptide, 4 g of glycerol, 0.9 g of phenoxyethanol, and 0.1 g of ethylhexylglycerol to obtain phase C;

[0041] 4. Mix phases A, B, and C, add citric acid to adjust the pH to 6.2, place in a water bath at 40°C for 30 minutes and stir to obtain emulsion 1#.

[0042] The above-prepared product has the functions of quickly removing dark circles and long-lasting anti-aging, and is recorded as product 1#.

[0043] According to the preparation method of product 1#, the dosage of components was adjusted to prepare products 1#-12# and products D1#-D4#. The specific formulas are shown in Table 1. Products 1#-12# are the experimental group, and products D1#-D4# are the control group.

[0044] Table 1 Formula of each component of the product

[0045]

[0046]

[0047]

[0048]

[0049] Example 2

[0050] An emulsion product was prepared by the method of Reference Example 1, except that Example 2 was set according to the parameter conditions in Table 1, and other conditions were the same as Example 1, to prepare Product 2#.

[0051] Example 3

[0052] An emulsion product was prepared by the method of Reference Example 1, except that Example 3 was set according to the parameter conditions in Table 1, and other conditions were the same as Example 1, to prepare Product 3#.

[0053] Example 4

[0054] An emulsion product was prepared by the method of Reference Example 1, except that Example 2 was set according to the parameter conditions in Table 1, and other conditions were the same as Example 1, to prepare Product 2#.

[0055] Example 5

[0056] An emulsion product was prepared by the method of Reference Example 1, except that Example 2 was set according to the parameter conditions in Table 1, and other conditions were the same as Example 1, to prepare Product 2#.

[0057] Example 6

[0058] The emulsion product was prepared by the method of Reference Example 1, and Example 6 was set according to the parameter conditions in Table 1, except that glutathione and acetyl hexapeptide-8 were replaced by carnosine and acetyl tetrapeptide-2, and other conditions were the same as Example 1, to prepare product 6#.

[0059] Example 7

[0060] The emulsion product was prepared according to the method of Example 1, and Example 7 was set according to the parameter conditions in Table 1, except that oligopeptide-1 and oligopeptide-3 were used to replace acetyl hexapeptide-8 and acetyl tetrapeptide-5. The other conditions were the same as Example 1, and product 7# was prepared.

[0061] Example 8

[0062] The emulsion product was prepared by the method of Reference Example 1, and Example 8 was set according to the parameter conditions in Table 1, except that palmitoyl pentapeptide-4 was used instead of the snake venom peptide, and other conditions were the same as Example 1, to prepare product 8#.

[0063] Example 9

[0064] The emulsion product was prepared by the method of Reference Example 1, and Example 9 was set according to the parameter conditions in Table 1, except that pentapeptide-3 was used to replace the arginine / lysine polypeptide. Other conditions were the same as Example 1, and product 9# was prepared.

[0065] Example 10

[0066] An emulsion product was prepared by the method of Reference Example 1, and Example 10 was set according to the parameter conditions in Table 1, except that the raw materials of each component in phase A, phase B, and phase C were directly physically mixed, and other conditions were the same as Example 1, to prepare product 10#.

[0067] Embodiment 11

[0068] An emulsion product was prepared according to the method of Reference Example 1, and Example 11 was set according to the parameter conditions in Table 1, except that the amounts of β-nicotinamide mononucleotide, ergothioneine, and tocopherol acetate components were adjusted, and other conditions were the same as in Example 1, to prepare Product 11#.

[0069] Example 12

[0070] The emulsion product was prepared according to the method of Example 1, and Example 12 was set according to the parameter conditions in Table 1, except that the number of components of polypeptide complex a and polypeptide complex b was adjusted. Other conditions were the same as Example 1, and product 12# was prepared.

[0071] Comparative Example D1#

[0072] The emulsion product was prepared according to the method of Example 1, and the comparative example D1# was set according to the parameter conditions in Table 1, except that tripeptide-1 copper was used instead of β-nicotinamide mononucleotide, and other conditions were the same as Example 1 to prepare product D1#.

[0073] Comparative Example D2#

[0074] The method for reference example 1 prepares an emulsion product, and comparative example D2# is set according to the parameter conditions in table 1, except that ergothioneine, tocopherol acetate, are replaced by carnosine and tocopherol phosphate, and other conditions are the same as in example 1, to prepare product D2#.

[0075] Comparative Example D3#

[0076] The emulsion product was prepared according to the method of Reference Example 1, and the comparative example D3# was set according to the parameter conditions in Table 1, except that carnosine, palmitoyl tripeptide-1, and palmitoyl tetrapeptide-7 were used to replace glutathione, acetyl hexapeptide-8, and acetyl tetrapeptide-5. The other conditions were the same as in Example 1 to prepare product D3#.

[0077] Comparative Example D4#

[0078] The emulsion product was prepared according to the method of Example 1, and the comparative example D4# was set according to the parameter conditions in Table 1, except that palmitoyl pentapeptide-4 and acetyl dipeptide-1 were used to replace the snake venom peptide and arginine / lysine polypeptide, and the other conditions were the same as in Example 1 to prepare product D4#.

[0079] Experimental Example 1

[0080] The above eye creams were tested for product safety, dark circle removal effect, and anti-aging effect. The test methods and results are as follows:

[0081] 1. Human skin patch test

[0082] Test method: The closed patch test in Chapter 7 of the human skin patch test of the 2015 edition of the "Hygienic Standards for Cosmetics" was used to test products 1-12# and products D1-D4#. 64 volunteers aged 18-40 with healthy skin were selected, half male and half female, and randomly divided into 16 groups, with 4 people in each group (2 males and 2 females); groups 1-12 used products 1-12#, and groups 13-16 used products D1-D4#. The reaction standards are shown in Table 2, and the test results are shown in Table 3.

[0083] Table 2. Human skin reaction standards

[0084]

[0085] Table 3. Human skin patch test results

[0086]

[0087] Experimental results: The results of the human skin patch test showed that: by conducting a closed patch test on each group of subjects after using the product prepared by the present application, the skin reactions were observed at 0.5, 24, and 48 hours, and there was no case of adverse skin reaction, indicating that the product with the effect of removing dark circles and anti-aging prepared by the present invention is non-irritating to the skin and has good safety.

[0088] 2. Dark Circle Removal Effect Test

[0089] Test method: 80 female volunteers (aged 40-50 years old, average age 45 years old) were selected and randomly divided into 16 groups. After each group of subjects cleaned their faces with warm water, they rested for 0.5-1h in a constant temperature and humidity room with a constant temperature of 25°C and a humidity of 40-60%, and then conducted a pre-use test. Each group applied the corresponding product to the lower eyelids and outer corners of the eyes of the testers, peeled off and massaged for absorption after 15 minutes. Groups 1-12 used products 1-12#, and groups 13-16 used products D1-D4#. After use, they were tested and self-evaluated. The test used PIXIENCE's C-Cube multifunctional skin imaging analysis system to test the skin texture and brightness (average value), and the testers also self-evaluated the glossiness of the skin around the eyes and the level of dark circles. The test results are shown in Table 4.

[0090] Table 4. Dark Circle Removal Effect Test Statistics

[0091]

[0092]

[0093] Conclusion: Note: The L value represents brightness, with complete darkness (L=0) to absolute white (L=100);

[0094] ITA° (Individual Type Angle) represents skin color: less than 10° is brown, 10-28° is brown, 28-41° is normal color, 41-55° is white, and greater than 55° is very white.

[0095] As shown in Table 4, the L value and ITA° of the eye skin of the testers who used products 1-12# were significantly improved, and the improvement effect was more significant for the testers who used products 1-5#, especially the improvement effect of product 2# was the best, indicating that the skin around the dark circles was brighter and whiter. The eye cream has the effect of quickly fading dark circles and brightening the skin tone of the eye; and when the active substances were 1 part of β-nicotinamide mononucleotide, 0.5 part of glutathione, 0.01 part of acetyl hexapeptide-8, 0.01 part of acetyl tetrapeptide-5, 0.025 part of snake venom peptide, 0.04 part of arginine / lysine polypeptide, 1 part of tocopherol acetate, and 0.03 part of ergothioneine by mass, the improvement effect was the best, further proving the synergistic effect of each active substance in removing dark circles.

[0096] 3. Anti-aging effect verification test

[0097] Test method: 80 female volunteers (aged 40-50 years old, average age 45 years old) were selected and randomly divided into 16 groups. The products prepared in the embodiments were used on the eye area after cleansing every morning and evening. Groups 1-12 used products 1-12#, and groups 13-16 used products D1-D4#, respectively. The amount used in each group was the same. After continuous use for 8 weeks, the VISIA instrument was used to evaluate the reduction in the wrinkle area, number of wrinkles and wrinkle depth in the crow's feet area at the corners of the eyes. The test results are shown in Table 5.

[0098] Table 5. Statistics of anti-aging effect verification test

[0099]

[0100]

[0101] Experimental conclusion: In the long-term anti-aging test, products 1-12# can effectively play the role of long-term anti-aging and anti-aging of eye wrinkles, and products 1-5# have more significant effects, especially product 1# has the best effect on long-term anti-aging and anti-aging of eye wrinkles. When using products D1-D4#, the long-term anti-aging effect is much lower than that of product 1#, indicating that the active ingredients of the present invention have a synergistic effect in anti-aging and have a better overall effect. When the active substances are 1 part of β-nicotinamide mononucleotide, 0.5 parts of glutathione, 0.01 parts of acetyl hexapeptide-8, 0.01 parts of acetyl tetrapeptide-5, 0.025 parts of snake venom peptide, 0.04 parts of arginine / lysine polypeptide, 1 part of tocopherol acetate, and 0.03 parts of ergothioneine by mass, the improvement effect is best.

[0102] The above is only the embodiment of the present application, and the protection scope of the present application is not limited by these specific embodiments, but is determined by the claims of the present application. For those skilled in the art, the present application can have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the technical ideas and principles of the present application should be included in the protection scope of the present application.

Claims

1. A composition for quickly removing dark circles and long-term anti-aging, characterized in that: It includes β-nicotinamide mononucleotide, polypeptide complex a, polypeptide complex b, tocopherol acetate and ergothioneine.

2. The composition according to claim 1, characterized in that Calculated by weight, the composition comprises 0.1-2 parts of β-nicotinamide mononucleotide, 0.052-2.15 parts of polypeptide complex a, 0.002-0.2 parts of polypeptide complex b, 0.1-2 parts of tocopherol acetate, and 0.01-0.05 parts of ergothioneine.

3. The composition according to claim 1, characterized in that The composition comprises, by weight, 0.5-1.5 parts of β-nicotinamide mononucleotide, 0.11-1.04 parts of polypeptide complex a, 0.02-0.1 parts of polypeptide complex b, 0.5-1.5 parts of tocopherol acetate, and 0.02-0.04 parts of ergothioneine; Preferably, the composition comprises, by mass, 1 part of β-nicotinamide mononucleotide, 0.52 parts of polypeptide complex a, 0.065 parts of polypeptide complex b, 1 part of tocopherol acetate, and 0.03 parts of ergothioneine.

4. The composition according to claim 1, characterized in that By weight, the polypeptide complex a includes 0.05-2 parts of glutathione, 0.001-0.1 parts of acetyl hexapeptide-8, and 0.001-0.05 parts of acetyl tetrapeptide-5; the polypeptide complex b includes 0.001-0.1 parts of snake venom peptide and 0.001-0.1 parts of arginine / lysine polypeptide.

5. The composition according to claim 1, characterized in that By weight, the polypeptide complex a comprises 0.1-1 parts of glutathione, 0.005-0.02 parts of acetyl hexapeptide-8, and 0.005-0.02 parts of acetyl tetrapeptide-5; the polypeptide complex b comprises 0.01-0.05 parts of snake venom peptide and 0.01-0.05 parts of arginine / lysine polypeptide; Preferably, the polypeptide complex a comprises 0.5 parts of glutathione, 0.01 parts of acetyl hexapeptide-8, and 0.01 parts of acetyl tetrapeptide-5; preferably, the polypeptide complex b comprises 0.025 parts of snake venom peptide and 0.04 parts of arginine / lysine polypeptide.

6. A method for preparing a lotion for rapidly removing dark circles and providing long-lasting anti-aging effects, characterized in that: The following steps are involved: S1. The oil composition, the thickener and the humectant are stirred and mixed to obtain phase A; S2. stirring and mixing β-nicotinamide mononucleotide, ergothioneine, polypeptide complex a and water to obtain phase B; S3. stirring and mixing tocopherol acetate, polypeptide complex b, and emulsifier to obtain phase C; S4. Mix phases A, B and C to obtain an emulsion.

7. The method for preparing the emulsion according to claim 6, characterized in that: In the step S1, the oil composition is composed of at least one of polydimethylsiloxane, cyclopentasiloxane, polydimethylsiloxane cross-linked polymer, cyclopentasiloxane, and TEA dodecylbenzenesulfonate; the thickener is composed of at least one of acryloyldimethyltaurate / VP copolymer, carbomer, sodium acrylate / acryloyldimethyltaurate / isohexadecane / polysorbate-80; and the moisturizer is composed of at least one of hyaluronic acid and sodium hyaluronate.

8. The method for preparing the emulsion according to claim 6, characterized in that: In the step S3, the emulsifier is at least one of glycerin, phenoxyethanol, and ethylhexylglycerin.

9. The method for preparing the emulsion according to claim 6, characterized in that: In the step S4, the pH of phases A, B and C is adjusted to 6.2, and the mixture is stirred and mixed in a water bath at 40° C. for 30 minutes to obtain an emulsion.

10. Use of the composition according to any one of claims 1 to 5 in cosmetics, health products, and medicines, wherein the composition can be made into an emulsion, solution, paste, gel, or spray form.

Images